Here, we investigated how these oncogenic lesions synergized to induce metabolic alterations in PDAC cells using tumor cells derived from the KCPTEN (Kras activation and Pten loss) genetically engineered mouse model of PDAC (Kennedy et al., 2011, Morran et al., 2014). Here, KRAS is linked to neoplasm.